If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic, and provider MUST call the laboratory at 722-5321 to initiate the sample transfer and testing.

If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and and adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm² at 10 microns thickness).

SPECIMEN INFORMATION:

1. At least 60% tumor must be present in the submitted CNS tumor sample. A result from a sample containing <60% tumor may be reported as unsatisfactory (no results reported). A pathology report from the submitted sample is required. An internal pathology review will also be performed on submitted tumor samples to verify tumor content.
2. All specimens must be labeled with a patient name and other identifier (DOB, MRN, Specimen ID#, etc.). Sample acquisition prior to receiving therapy is strongly preferred.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls or slides, an H&E slide from a consecutive cut is also required. Tissue blocks can be returned to the treating institution upon request.

SPECIMEN SHIPPING:

Ship all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping.

This Methylation Microarray Analysis is performed on Central Nervous System (CNS) tumors using the Illumina MethylationEPIC BeadChip version 2 platform and software developed by the Nationwide Children’s Hospital Institute for Genomic Medicine (IGM) to subtype CNS tumors. This array assesses the CNS tumor methylation profile and compares it to over 3,900 reference CNS cases to create a classification prediction score indicating the resemblance to a CNS tumor subtype (see reference below). Results will use the IGM CNS classifier to indicate a methylation class specific to a CNS subtype categorized as “consistent with," “no match, but potentially suggestive of,” or “tumor classification not determined,” as well as MGMT methylation status.

This analysis is intended to aid and refine the pathological diagnoses of CNS tumors. Results should be interpreted in conjunction with other laboratory findings, such as histology, and molecular testing. This analysis should NOT be used as a stand-alone diagnostic test. Patient samples of rare subtypes that are not in the classifier reference set may result in a low classifier prediction score.

References:

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8),1231-1251 (2021). PMID: 34185076.

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic, and provider MUST call the laboratory at 722-5321 to initiate the sample transfer and testing.

If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and and adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm² at 10 microns thickness).

SPECIMEN INFORMATION:

1. At least 60% tumor must be present in the submitted CNS tumor sample. A result from a sample containing <60% tumor may be reported as unsatisfactory (no results reported). A pathology report from the submitted sample is required. An internal pathology review will also be performed on submitted tumor samples to verify tumor content.
2. All specimens must be labeled with a patient name and other identifier (DOB, MRN, Specimen ID#, etc.). Sample acquisition prior to receiving therapy is strongly preferred.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls or slides, an H&E slide from a consecutive cut is also required. Tissue blocks can be returned to the treating institution upon request.

SPECIMEN SHIPPING:

Ship all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping.

This Methylation Microarray Analysis is performed on Central Nervous System (CNS) tumors using the Illumina MethylationEPIC BeadChip version 2 platform and software developed by the Nationwide Children’s Hospital Institute for Genomic Medicine (IGM) to subtype CNS tumors. This array assesses the CNS tumor methylation profile and compares it to over 3,900 reference CNS cases to create a classification prediction score indicating the resemblance to a CNS tumor subtype (see reference below). Results will use the IGM CNS classifier to indicate a methylation class specific to a CNS subtype categorized as “consistent with," “no match, but potentially suggestive of,” or “tumor classification not determined,” as well as MGMT methylation status.

This analysis is intended to aid and refine the pathological diagnoses of CNS tumors. Results should be interpreted in conjunction with other laboratory findings, such as histology, and molecular testing. This analysis should NOT be used as a stand-alone diagnostic test. Patient samples of rare subtypes that are not in the classifier reference set may result in a low classifier prediction score.

References:

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8),1231-1251 (2021). PMID: 34185076.

This Methylation Microarray Analysis is performed on Central Nervous System (CNS) tumors using the Illumina MethylationEPIC BeadChip version 2 platform and software developed by the Nationwide Children’s Hospital Institute for Genomic Medicine (IGM) to subtype CNS tumors. This array assesses the CNS tumor methylation profile and compares it to over 3,900 reference CNS cases to create a classification prediction score indicating the resemblance to a CNS tumor subtype (see reference below). Results will use the IGM CNS classifier to indicate a methylation class specific to a CNS subtype categorized as “consistent with," “no match, but potentially suggestive of,” or “tumor classification not determined,” as well as MGMT methylation status.

This analysis is intended to aid and refine the pathological diagnoses of CNS tumors. Results should be interpreted in conjunction with other laboratory findings, such as histology, and molecular testing. This analysis should NOT be used as a stand-alone diagnostic test. Patient samples of rare subtypes that are not in the classifier reference set may result in a low classifier prediction score.

References:

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8),1231-1251 (2021). PMID: 34185076.

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic, and provider MUST call the laboratory at 722-5321 to initiate the sample transfer and testing.

If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and and adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm² at 10 microns thickness).

SPECIMEN INFORMATION:

1. At least 60% tumor must be present in the submitted CNS tumor sample. A result from a sample containing <60% tumor may be reported as unsatisfactory (no results reported). A pathology report from the submitted sample is required. An internal pathology review will also be performed on submitted tumor samples to verify tumor content.
2. All specimens must be labeled with a patient name and other identifier (DOB, MRN, Specimen ID#, etc.). Sample acquisition prior to receiving therapy is strongly preferred.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls or slides, an H&E slide from a consecutive cut is also required. Tissue blocks can be returned to the treating institution upon request.

SPECIMEN SHIPPING:

Ship all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping.

This Methylation Microarray Analysis is performed on Central Nervous System (CNS) tumors using the Illumina MethylationEPIC BeadChip version 2 platform and software developed by the Nationwide Children’s Hospital Institute for Genomic Medicine (IGM) to subtype CNS tumors. This array assesses the CNS tumor methylation profile and compares it to over 3,900 reference CNS cases to create a classification prediction score indicating the resemblance to a CNS tumor subtype (see reference below). Results will use the IGM CNS classifier to indicate a methylation class specific to a CNS subtype categorized as “consistent with," “no match, but potentially suggestive of,” or “tumor classification not determined,” as well as MGMT methylation status.

This analysis is intended to aid and refine the pathological diagnoses of CNS tumors. Results should be interpreted in conjunction with other laboratory findings, such as histology, and molecular testing. This analysis should NOT be used as a stand-alone diagnostic test. Patient samples of rare subtypes that are not in the classifier reference set may result in a low classifier prediction score.

References:

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8),1231-1251 (2021). PMID: 34185076.